Download PDF
Transfusionsmedizin 2012; 2(3): 153-164
DOI: 10.1055/s-0032-1315027
CME-Fortbildung
Georg Thieme Verlag KG Stuttgart · New York

Hämolytisch-urämisches Syndrom

A. Tiede
1   Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
27 July 2012 (online)

Also available at
    Permissions and Reprints

Corrected by:

Hämolytisch-urämisches SyndromTransfusionsmedizin 2012; 2(02): e1-e1
DOI: 10.1055/s-0032-1324817

Zusammenfassung

Das typische, diarrhöassoziierte hämolytisch-urämische Syndrom (D-HUS) beruht auf einer Infektion mit Shigatoxin-bildenden enterohämorrhagischen Escherichia coli (EHEC). Shigatoxin provoziert durch Endothelschädigung und Schaffung eines inflammatorischen, prothrombotischen Milieus eine thrombotische Mikroangiopathie (TMA), die mit akutem Nierenversagen, neurologischen Funktionsstörungen und anderen Organmanifestationen einhergehen kann. Das D-HUS ist vom atypischen HUS (A-HUS) zu unterscheiden, dessen Ursache meist ein Defekt löslicher oder membranständiger Komplementregulatoren ist. Auch das A-HUS resultiert in einer akuten oder chronischen TMA mit ähnlichen Organmanifestationen. Eine 3. Erkrankung, die mit TMA einhergeht, ist die thrombotisch-thrombozytopenische Purpura (TTP), beruhend auf einem Defekt der VWF-spaltenden (VWF: von-Willebrand-Faktor) Protease ADAMTS13. Weitere Erkrankungen können eine TMA simulieren oder mit dieser einhergehen. Im Jahr 2006 wurde eine neue, stärker ätiologisch und pathophysiologisch orientierte Klassifikation von Erkrankungen mit TMA vorgeschlagen. Die in der Differenzialdiagnostik erforderlichen Untersuchungen sind aufwendig und zum Teil noch nicht flächendeckend verfügbar. Die Diagnostik von D-HUS, A-HUS und TTP ist deshalb in der Praxis schwierig, gewinnt wegen zunehmend differenzierter Therapieoptionen jedoch an Bedeutung. Dies gilt insbesondere für den Einsatz der Plasmapherese und des kürzlich zur Therapie des A-HUS zugelassenen Komplementinhibitors Eculizumab.

Key words

D-HUS - Shigatoxin - thrombotische Mikroangiopathie - A-HUS
 

  • Literatur

  • 1 Gasser C, Gautier E, Steck A et al. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 1955; 85: 905-909
    PubMedGoogle Scholar
  • 2 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Mt Sinai J Med 2003; 70: 352-355
    PubMedGoogle Scholar
  • 3 George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060-4069
    CrossrefPubMedGoogle Scholar
  • 4 Besbas N, Karpman D, Landau D et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431
    PubMedGoogle Scholar
  • 5 Frank C, Werber D, Cramer JP et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365: 1771-1780
    CrossrefPubMedGoogle Scholar
  • 6 Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 575-585
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Terrell DR, Williams LA, Vesely SK et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3: 1432-1436
    CrossrefPubMedGoogle Scholar
  • 8 Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6: 60
    CrossrefPubMedGoogle Scholar
  • 9 Hovinga JA, Vesely SK, Terrell DR et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511 quiz 662
    CrossrefPubMedGoogle Scholar
  • 10 Ashkenazi S. Role of bacterial cytotoxins in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Annu Rev Med 1993; 44: 11-18
    CrossrefPubMedGoogle Scholar
  • 11 Bielaszewska M, Mellmann A, Zhang W et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011; 11: 671-676
    CrossrefPubMedGoogle Scholar
  • 12 Murata K, Higuchi T, Takada K et al. Verotoxin-1 stimulation of macrophage-like THP-1 cells up-regulates tissue factor expression through activation of c-Yes tyrosine kinase: Possible signal transduction in tissue factor up-regulation. Biochim Biophys Acta 2006; 1762: 835-843
    CrossrefPubMedGoogle Scholar
  • 13 Stahl AL, Sartz L, Nelsson A et al. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One 2009; 4: e6990
    CrossrefPubMedGoogle Scholar
  • 14 Karpman D, Papadopoulou D, Nilsson K et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001; 97: 3100-3108
    CrossrefPubMedGoogle Scholar
  • 15 Morigi M, Galbusera M, Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187: 172-180
    CrossrefPubMedGoogle Scholar
  • 16 Karpman D, Manea M, Vaziri-Sani F et al. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32: 128-145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Hughes AK, Ergonul Z, Stricklett PK et al. Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression. J Am Soc Nephrol 2002; 13: 2239-2245
    CrossrefPubMedGoogle Scholar
  • 18 Warnier M, Romer W, Geelen J et al. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells. Kidney Int 2006; 70: 2085-2091
    PubMedGoogle Scholar
  • 19 Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836-844
    CrossrefPubMedGoogle Scholar
  • 20 Roumenina LT, Loirat C, Dragon-Durey MA et al. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365: 8-26
    CrossrefPubMedGoogle Scholar
  • 21 Esparza-Gordillo J, Jorge EG, Garrido CA et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006; 43: 1769-1775
    CrossrefPubMedGoogle Scholar
  • 22 Le Quintrec M, Lionet A, Kamar N et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8: 1694-1701
    CrossrefPubMedGoogle Scholar
  • 23 Dragon-Durey MA, Blanc C, Garnier A, Hofer J et al. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost 2010; 36: 633-640
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Thurman JM, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1920-1924
    CrossrefPubMedGoogle Scholar
  • 25 Orth D, Khan AB, Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182: 6394-6400
    CrossrefPubMedGoogle Scholar
  • 26 Zini G, dʼOnofrio G, Briggs C et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol 2012; 34: 107-116
    CrossrefPubMedGoogle Scholar
  • 27 Lesesve JF, Salignac S, Alla F et al. Comparative evaluation of schistocyte counting by an automated method and by microscopic determination. Am J Clin Pathol 2004; 121: 739-745
    CrossrefPubMedGoogle Scholar
  • 28 Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1: 625-631
    CrossrefPubMedGoogle Scholar
  • 29 Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost 2003; 1: 632-634
    CrossrefPubMedGoogle Scholar
  • 30 Oppermann M, Wurzner R. Modern determination of complement activation. Semin Thromb Hemost 2010; 36: 611-619
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Taylor CM, Machin S, Wigmore SJ et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 148: 37-47
    CrossrefPubMedGoogle Scholar
  • 32 Allford SL, Hunt BJ, Rose P et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573
    CrossrefPubMedGoogle Scholar
  • 33 Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086
    PubMedGoogle Scholar
  • 34 Wong CS, Jelacic S, Habeeb RL et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930-1936
    CrossrefPubMedGoogle Scholar
  • 35 Nitschke M, Sayk F, Hartel C et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012; 307: 1046-1052
    CrossrefPubMedGoogle Scholar
  • 36 McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother 2010; 54: 3790-3798
    CrossrefPubMedGoogle Scholar
  • 37 Stanworth SJ, Brunskill SJ, Hyde CJ et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126: 139-152
    CrossrefPubMedGoogle Scholar
  • 38 Loirat C, Sonsino E, Hinglais N et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988; 2: 279-285
    CrossrefPubMedGoogle Scholar
  • 39 Rizzoni G, Claris-Appiani A, Edefonti A et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112: 284-290
    CrossrefPubMedGoogle Scholar
  • 40 Dundas S, Murphy J, Soutar RL et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999; 354: 1327-1330
    CrossrefPubMedGoogle Scholar
  • 41 Nakatani T, Tsuchida K, Yoshimura R et al. Plasma exchange therapy for the treatment of Escherichia coli O-157 associated hemolytic uremic syndrome. Int J Mol Med 2002; 10: 585-588
    PubMedGoogle Scholar
  • 42 Greinacher A, Friesecke S, Abel P et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; 378: 1166-1173
    CrossrefPubMedGoogle Scholar
  • 43 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med 2012; 41: e115-e135
    CrossrefPubMedGoogle Scholar
  • 44 Dundas S, Todd WT, Stewart AI et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33: 923-931
    CrossrefPubMedGoogle Scholar
  • 45 Ariceta G, Besbas N, Johnson S et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696
    CrossrefPubMedGoogle Scholar
  • 46 Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279
    CrossrefPubMedGoogle Scholar
  • 47 Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1: 88-99
    CrossrefPubMedGoogle Scholar
  • 48 Legendre CM, Babu S, Furman RR et al. Safety and efficacy of eculizumab in aHUS patients resistant to plasma therapy: interim analysis from a phase II trial (SA-FC406). J Am Soc Nephrol 2010; 21: 93A
    CrossrefPubMedGoogle Scholar
  • 49 Muus P, Legendre CM, Douglas K et al. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: interim analysis of a phase II trial (F-PO1274). J Am Soc Nephrol 2010; 21: 402A
    PubMedGoogle Scholar
  • 50 Kose O, Zimmerhackl LB, Jungraithmayr T et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010; 36: 669-672
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Westra D, Wetzels JF, Volokhina EB et al. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med 2012; 70: 121-129
    PubMedGoogle Scholar
  • 52 Malina M, Roumenina LT, Seeman T et al. Genetics of hemolytic uremic syndromes. Presse Med 2012; 41: e105-e114
    CrossrefPubMedGoogle Scholar